Month: October 2026

Malaysia, Kuala Lumpur, Oct. 28, 2026 (GLOBE NEWSWIRE) — Megan Holdings Limited (Nasdaq: MGN) (the “Company” or “Megan”), a Malaysia-based company principally engaged in the development, construction, and maintenance of aquaculture farms and related works, today announced the pricing of a follow-on public offering (the “Offering”) of up to 15,000,000 Class A ordinary shares, par value US$0.003 per share (the “Class A Ordinary Shares”), at a public offering price of US$0.5 per share.

The Offering is being conducted on a reasonable best-efforts basis. Prime Number Capital, LLC is acting as the exclusive placement agent for the Offering. The Offering is expected to close on or about October 29, 2026, subject to the satisfaction of customary closing conditions. There is no minimum offering amount required as a condition to closing.

The Company expects to receive aggregate gross proceeds of up to approximately US$7.5 million, assuming the sale of all of the Class A Ordinary Shares offered, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for the development of new products (including its Smart Farming System), business ventures and acquisitions and for general working capital.

The Class A Ordinary Shares described above are being offered pursuant to a registration statement on Form F-1 (File No. 333-299548), as amended, declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 27, 2026. The Offering is being made only by means of a prospectus forming part of the effective registration statement. A final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus may also be obtained, when available, from Prime Number Capital, LLC, 12 East 49th Street, 27th Floor, New York, NY 10017, by telephone at +1 (347) 329-1575, or by email at info@pncps.com.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Megan Holdings Limited

Megan Holdings Limited (the “Company” or “Megan”) is a Malaysia-based company principally engaged in the development, construction, and maintenance of aquaculture farms and related works. Since its inception in 2020, the Company has strived to establish itself as a trusted and experienced provider of shrimp farm related maintenance services in Malaysia. Complementary to its upgrading and maintenance services, Megan also assists customers with the design and development of new farms, including the development and construction of a shrimp hatchery center in Semporna, Sabah, and the development of a 111-acre shrimp farm in Tawau, Sabah, Malaysia. Megan also assists customers in sourcing building materials and machineries available for rental for use on their farms, positioning itself as a one-stop center for aquaculture and agriculture needs. For more information, please visit the company’s website: https://www.meganmezanin.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, statements regarding the Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as “believe”, “plan”, “expect”, “intend”, “should”, “seek”, “estimate”, “will”, “aim” and “anticipate” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in its registration statement on Form F-1 and other filings with the SEC.

For media inquiries, please contact:

Megan Holdings Limited

Investor Relations Department

Email: info@meganmezanin.com

SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) — XCOM RAN by Globalstar has been named the winner of the Gold Stevie^® Award for Technology Innovation of the Year in the third annual Stevie Awards for Technology Excellence. XCOM RAN was recognized for its advanced private 5G solution that provides the essential foundation for autonomous operations and Physical AI in manufacturing and logistics environments.

The Stevie Awards for Technology Excellence honor excellence in artificial intelligence (AI), information technology, financial technology, healthcare technology, business technology, communications technology, green technology, manufacturing technology, and many other industries. Organizations of every size—public and private, for-profit and nonprofit—from anywhere in the world are eligible to participate.

XCOM RAN was one of more than 700 nominations from organizations in 37 nations and territories that were evaluated this year by more than 180 technology and business professionals serving as judges. Winners were selected based on the average scores assigned during the independent judging process.

“As organizations embrace automation, intelligent systems, and Physical AI, the network has become a critical foundation for innovation,” said Tamer Kadous, General Manager, XCOM RAN Business Unit at Globalstar. “This Gold Stevie Award validates the innovation behind XCOM RAN and our vision for the future of private wireless. As organizations demand greater capacity, reliability and security from their networks, XCOM RAN is redefining what private 5G can deliver and helping customers build smarter, more connected autonomous operations on their path to physical AI.”

XCOM RAN is a comprehensive private 5G solution designed to support AI-driven industrial automation and mobile robotics. With low latency and enterprise-grade reliability, it provides the foundational infrastructure needed to power physical AI across complex industrial environments. The end-to-end wireless connectivity solution enables devices in smart warehouses, manufacturing facilities, and logistics hubs to move seamlessly throughout a site while maintaining continuous, high-performance connectivity, regardless of facility size or number of connected devices.

According to the Stevie Awards judging committee, XCOM RAN received high marks for “redefining private 5G networking” through its groundbreaking Supercell architecture that delivers up to four times greater network capacity, seamless mobility, and ultra-reliable connectivity for industrial AI, automation, robotics, and mission-critical operations.

The judges cited the solution’s unique combination of architectural innovation, deployment simplicity, and spectrum leadership. They highlighted its exclusive access to licensed Band n53 spectrum through Globalstar, support for other private and shared spectrum bands, and its server-centric Open RAN design, which simplifies deployment, reduces network complexity, and enables scalable, cost-effective private wireless implementations across factories, warehouses, ports, and logistics facilities.

Manufacturing, warehouse and facilities operators benefit from faster time-to-operation, lower implementation costs and a consistent network design that scales across multiple distribution centers and fulfillment facilities to deliver the optimal platform for Physical AI.

Stevie Award winners will be honored at a red carpet awards ceremony on Oct. 28 at the Pullman Paris Montparnasse in Paris, France, where they will be celebrated alongside winners of the 2026 Stevie^® Awards for Great Employers, The International Business Awards^®, and the German Stevie^® Awards.

Details about the Stevie Awards for Technology Excellence and the list of 2026 Stevie winners are available at http://Tech.StevieAwards.com.

About XCOM RAN
XCOM RAN by Globalstar provides next-generation private 5G wireless connectivity that supports mobile robotics, connected workers and autonomous operations in industrial and mission-critical environments. Designed to support demanding physical AI and automation requirements, XCOM RAN delivers flawless connectivity and higher capacity through its differentiated software-defined, Supercell architecture operating in spectrum bands n48, n53 and n78. The solution simplifies deployment and management, providing the infrastructure required to power AI-driven operations at scale. For more information, visit www.xcomran.com and follow us on LinkedIn.

About the Stevie Awards

The Stevie^® Awards, widely recognized as the world’s premier business awards, are nicknamed the Stevies, derived from the Greek word stephanos, meaning “crowned.” The Stevie Awards are conferred through nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards^®, The International Business Awards^®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Technology Excellence, and the Stevie Awards for Sales & Customer Service.

The Stevie Awards receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Media Contact:
Janet Brumfield
IdealPR+ for XCOM RAN
janet@idealprplus.com
614.582.9636

Five-unit pilot combines component development, prototyping and assembly as AIBotics works toward production validation

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) — AIBotics, Inc. (OTCID: AIBT) (“AIBotics” or the “Company”) announced today an update on development and manufacturing of PHILL ROBOT™, its proprietary AI-powered massage and wellness platform, as U.S.-based manufacturing partner 3DX Industries, Inc. (OTCID: DDDX) continues its support of the initial five-unit pilot program.

The pilot program is designed to establish the manufacturing processes, assembly procedures and quality standards needed to move PHILL from continued product development toward a repeatable production model. 3DX is providing component manufacturing, prototyping, assembly and manufacturing-development support while AIBotics retains responsibility for software, AI architecture, system integration and overall product performance.

PHILL requires close coordination among mechanical design, electronic components, software and robotic functionality. The manufacturing program draws on 3DX’s capabilities in metal additive manufacturing, advanced resin printing, precision CNC machining, finishing and assembly, allowing the physical design to be refined as the system progresses through its pilot stage.

The proposed sequence for completing the pilot is organized around engineering and design review; production and inspection of pilot components; mechanical and electronic assembly; AIBotics-led software and system integration; functional testing and any required refinements; and final acceptance of the five pilot units. This sequence is a planning framework and is subject to confirmation with 3DX, including the status and timing of each stage.

3DX Industries will provide a target delivery timetable for the five-unit PHILL pilot once the remaining manufacturing, integration, and validation requirements have been confirmed.

The five-unit pilot is intended to provide the technical and operational basis for any subsequent production planning. Decisions regarding expanded manufacturing, commercial rollout and customer deliveries will depend on completion of the pilot, demonstrated product performance, available financing and final production arrangements.

“Our priority is to turn PHILL’s design into a product that can be manufactured, integrated and tested consistently,” said Ben Kaplan, Chief Executive Officer of AIBotics. “The five-unit pilot is an important step in establishing that foundation. We want to define the work that remains, complete it systematically and communicate meaningful progress as PHILL moves toward commercialization.”

PHILL ROBOT™ is being developed as an AI-powered robotic wellness platform designed to provide personalized, on-demand massage and therapeutic-touch functions in homes, fitness and recovery facilities, hospitality properties and related environments. The platform combines a foldable robotic arm with adaptive AI control, interchangeable massage functions and connected software. AIBotics recently announced additional steps to protect the PHILL ROBOT™ trademark as development and commercialization efforts continue.

About AIBotics

AIBotics, Inc. is a global operator deploying AI-enabled robotics and intelligent automation through strategic partnerships. The Company focuses on real-world execution, identifying, implementing and expanding technologies that automate operations in markets where demand is accelerating. Through a scalable, partnership-driven model, AIBotics is building a global robotics deployment platform with a repeatable framework for international scale. For more information, visit www.aibotics.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements concerning PHILL ROBOT™ development, manufacturing processes, engineering and system integration, completion and delivery of pilot units, future production, commercialization and potential market opportunities. These statements involve risks and uncertainties, including technical or design changes, component availability, manufacturing and testing outcomes, third-party performance, funding needs, production costs, customer demand and other risks that could cause actual results to differ materially. There can be no assurance that development milestones, production plans or anticipated commercial activities will be completed on any expected schedule or at all. Forward-looking statements speak only as of the date made, and AIBotics undertakes no obligation to update them except as required by law.

Media and Investor Relations

David L. Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 Office | (866) 692-6847 Toll Free
dk@atlcp.com

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore potential strategic opportunities, including a potential business combination.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including the occurrence of a meeting or discussion of ELPIS II results with the FDA and the future of the HLHS development program; our ability to pursue funding sources and potential revenue opportunities to advance laromestrocel in longevity and Aging-related frailty; our expectations regarding the review and exploration of all strategic options and their potential impact on shareholder value; our ability to engage an investment bank or other strategic advisor; the continued listing of our Class A common stock on Nasdaq; our expectations regarding the future of the company’s operations, including our clinical, development and commercialization activities; our plans to implement cash conservation measures to reduce operating expenses; and other statements regarding future events. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Additional factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the risk that the exploration of strategic options may not result in any definitive transaction or enhance shareholder value or may create uncertainty that may adversely affect our business, financial condition, results of operations, or shareholder and investor perception; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for laromestrocel in our development programs; our ability to reach alignment with the FDA and other regulatory authorities on a potential path toward regulatory approval; the availability of evidence from our ongoing and future preclinical studies and clinical trials sufficient to support the Company filing a BLA for the investigational product candidate for one or more indications; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in a highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Inquiries:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

Cyabra’s 2026 U.S. Midterm Report finds about 1 in 9 posts about the candidates came from inauthentic accounts, at roughly the same rate for Republican and Democratic candidates

New York, NY, Oct. 28, 2026 (GLOBE NEWSWIRE) — Cyabra, Inc. (Nasdaq: CYAB) (“Cyabra” or the “Company”), an artificial intelligence (“AI”)-powered narrative intelligence company that helps governments and enterprises detect coordinated manipulation and protect digital trust, today released Cyabra’s 2026 U.S. Midterm Report, an evidence-based narrative open-source intelligence analysis of inauthentic activity and coordination in online conversation.  The report adds election integrity to Cyabra’s national security work in the U.S. public sector, following the Company’s formation earlier this month of its National Security Advisory Council. Cyabra will further discuss the report at a December 9, 2026 luncheon with Carahsoft for public-sector leaders and election stakeholders.

The report examined six of the most competitive races of the 2026 cycle, the U.S. Senate contests in Kansas, Maine and Michigan and the governor’s races in Georgia, Nevada and Ohio. Cyabra analyzed about 274,000 posts and comments across X, TikTok, Facebook and Instagram from August 31 to October 19, with no sampling. For each race, Cyabra identified the leading narratives about both candidates, measured the rate of inauthentic profiles and content behind them, assessed whether that activity was coordinated, and traced how specific narratives were amplified. The report found:

• About 1 in 9 posts about the candidates came from inauthentic accounts, at roughly the same rate for Republican and Democratic candidates. By platform, the share was about 1 in 4 on TikTok, 1 in 7 on X, 1 in 11 on Instagram and under 1 in 20 on Facebook.
• Between 1 in 3 and 1 in 5 comments on a candidate’s own X account came from inauthentic accounts in most races, up to three times the overall rate.
• In five of the six races, Cyabra identified coordinated inauthentic accounts with high confidence; in four, coordinated attacks hit both the Republican and Democratic candidates.
• Inauthentic activity peaked around the candidate debates in mid-October, and such activity was still active in Ohio and Michigan when Cyabra’s analysis window closed on October 19.

During an election, a coordinated attack can look like a groundswell, and inauthentic accounts can pass for real voters. For governments, protecting elections from foreign and domestic disinformation and safeguarding national sovereignty both depend on knowing what is authentic, whether activity is coordinated and, where the evidence allows, who is behind it. Cyabra’s methodology gives election agencies early warning of influence operations and coordinated disinformation, with confidence-rated findings they can act on before false narratives take hold. It also measures narrative reach, sentiment and how much engagement comes from authentic versus inauthentic accounts.

“Influence operations are now a weapon system and public trust is being shaped by forces most citizens can’t see,” said Dan Brahmy, Co-Founder and Chief Executive Officer of Cyabra. “We tracked the run-up to Election Day, so the picture is in hand while the cycle is still live, when knowing which activity is inauthentic and which activity is coordinated is most useful to the institutions responding to it. Our standard is the same for every candidate and every party. Evidence first, and conclusions only as far as the evidence goes.”

The next step comes on December 9, 2026, when Cyabra and Carahsoft will host a luncheon for public-sector leaders and election stakeholders, where Cyabra will introduce its global protocol for narrative open-source intelligence collection and analysis in elections. The protocol draws on Cyabra’s analysis of national elections in five countries and sets out how online political conversation is collected, how inauthentic and coordinated activity is identified and how findings are confidence-rated and reported. Additional details, including registration information, will be announced.

“Agencies need findings they can defend under scrutiny and brief up the chain,” said Keith E. Noble, Ph.D., VP, Public Sector North America, at Cyabra. “This report shows what that looks like in a live election. On December 9, 2026, we’ll introduce a global protocol, drawn from elections in five countries, that agencies can apply to their own elections.”

Cyabra is nonpartisan and every finding in the report is drawn from publicly available data. Both candidates in every race were assessed using the same method, platforms and time window. Races with little inauthentic activity are reported as plainly as races with a great deal. Where the report identifies coordination, it describes the behavior, states a confidence level and notes where attribution cannot be established. The report takes no position on any candidate, party, policy or electoral outcome.

The report builds on Cyabra’s recognition as a Market Shaper in the inaugural June 2026 Gartner® Emerging Market Quadrant for Narrative Intelligence – Startup Vendors, in which Gartner, Inc. formally defined and assessed the narrative intelligence market for the first time.¹

The full report and state-by-state analysis can be accessed here (https://cyabra.com/reports/coordinated-inauthentic-activity-in-the-2026-us-midterm-races/).

About Cyabra

Cyabra is an AI-powered narrative intelligence company that helps national security and defense organizations, government agencies, brands, communications agencies, and global enterprises restore trust and authenticity online by analyzing manipulated content, coordinated behaviors, and inauthentic actors. The platform helps teams understand who is operating, how activity is amplified, and where coordinated activity is shaping perception, translating evidence into clear mitigation steps. By reducing ambiguity and misdirected response, Cyabra enables proportionate, evidence-led action when clarity matters most.

For more information, visit www.cyabra.com.

Contact:

Investors: ir@cyabra.com

Media: pr@cyabra.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding Cyabra’s intent, belief, or expectations, including, but not limited to, statements regarding Cyabra’s future results of operations and financial position, planned products and services, business strategy and plans, market size and growth opportunities, competitive position and market trends. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. For example, the Company is using forward-looking statements in this press release when discussing the planned December 9, 2026 event and the anticipated introduction of the global elections protocol, the anticipated uses and benefits of the report and the protocol for public-sector organizations, potential benefits of the National Security Advisory Council, the Company’s plans to continue analyzing election-related online activity and publishing related findings and the Company’s expansion in the U.S. public sector. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, that the planned December 9, 2026 event may be rescheduled or may not occur, that the anticipated benefits and uses of the report and protocol may not be realized, that the Company’s findings may be affected by limitations in available data, methodology or attribution, and those set forth in Cyabra’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Cyabra undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

_______________________

1 Source: Gartner, Emerging Market Quadrant for Narrative Intelligence – Startup Vendors, Alfredo Ramirez IV, Apeksha Kaushik, Akif Khan, Amber Boyes and David Senf, June 26, 2026. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the United States and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.